Keywords
C-reactive protein
procalcitonin
How to Cite
Abstract
In press
The article presents the results of the analysis of the dynamics of the main indicators of the blood coagulation system and cytokines (IL-6, D-dimers, C-reactive protein and procalcitonin) on the background of thromboprophylaxis in patients with COVID-19. The aim of our study was to determine the dynamics of the main indicators of the blood coagulation system and cytokines in the setting of thromboprophylaxis. The study was conducted at the Department of Infectious and Pediatric Infectious Diseases, Parasitology, Phthisiology and Pulmonology of the Kharkiv National Medical University and at the Municipal Non-Profit Enterprise "Kharkiv Regional Infectious Diseases Hospital" of the Kharkiv Regional Council, in 2020–2024 with compliance of the existing recommendations of bioethical norms and rules. All patients singed informed consent. We examined 179 patients aged 20–88 years (average age of [58.75±13.82] years) with COVID-19. The diagnosis of COVID-19 was confirmed by enzyme-linked immunosorbent assay and polymerase chain reaction. Medical and statistical calculations were performed using the SPSS 25.0 software package. The mean value and standard square deviation were calculated. The probability of differences was determined using the Mann-Whitney U-test with a threshold value of statistical significance of p=0.05. According to the results of the study, a significant (p<0.001) dynamic of restoration of D-Dimers’ levels was noted against the background of the applied therapy (on days 9–10, a decrease of 166.3 Fibrinogen Equivalent Unit (FEU), ng/ml, and on days 12–15 – of 376.7 FEU, ng/ml) and procalcitonin (on days 6–7 the content was by 0.04 ng/ml, p=0.006; on days 10–11 – 0.01 ng/ml, p<0.001; on days 12–15 – also 0.01 ng/ml, p=0.027).
Keywords: D-dimers, C-reactive protein, procalcitonin.
Archived: https://doi.org/10.5281/zenodo.12570945
References
Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-40. DOI: 10.1182/blood.2020006000. PMID: 32339221.
Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438-40. DOI: 10.1016/S2352-3026(20)30145-9. PMID: 32407672.
Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19. N Engl J Med. 2020;383(2):120-8. DOI: 10.1056/NEJMoa2015432. PMID: 32437596.
Miesbach W, Makris M. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Clin Appl Thromb Hemost. 2020;26:1076029620938149. DOI: 10.1177/1076029620938149. PMID: 32677459.
Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res. 2020;192:152-60. DOI: 10.1016/j.thromres.2020.05.039. PMID: 32485418.
McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. Circ Res. 2020;127(4):571-87. DOI: 10.1161/CIRCRESAHA.120.317447. PMID: 32586214.
Ahmed S, Zimba O, Gasparyan AY. Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad. Clin Rheumatol. 2020;39(9):2529-43. DOI: 10.1007/s10067-020-05275-1. PMID: 32654082.
Chekkal M, Deba T, Hadjali S, Lamara H, Oulaa H, Zouai K, Hariti G. Prevention and treatment of COVID-19-associated hypercoagulability: Recommendations of the Algerian society of transfusion and hemobiology. Transfus Clin Biol. 2020;27(4):203-6. DOI: 10.1016/j.tracli.2020.09.004. PMID: 33022374.
Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L. Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge. Thromb Haemost. 2020;120(6):949-56. DOI: 10.1055/s-0040-1710317. PMID: 32349133.
Pons S, Fodil S, Azoulay E, Zafrani L. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care. 2020;24(1):353. DOI: 10.1186/s13054-020-03062-7. PMID: 32546188.
Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, Wang Y. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis. 2020;99:47-56. DOI: 10.1016/j.ijid.2020.07.029. PMID: 32721533.
Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: A systematic review and meta-analysis. Rev Med Virol. 2020;30(6):1-9. DOI: 10.1002/rmv.2141. PMID: 32845568.
Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020;21(2):1470320320926899. DOI: 10.1177/1470320320926899. PMID: 32408793.
Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression. J Stroke Cerebrovasc Dis. 2020;29(8):104949. DOI: 10.1016/j.jstrokecerebrovasdis.2020.104949.
Amani-Beni R, Kermani-Alghoraishi M, Darouei B, Reid CM. A systematic review on post-discharge venous thromboembolism prophylaxis in patients with COVID-19. Egypt Heart J. 2023;75(1):72. DOI: 10.1186/s43044-023-00400-2. PMID: 37596465.
McBane RD 2nd, Torres Roldan VD, Niven AS, Pruthi RK, Franco PM, Linderbaum JA, et al. Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance from Mayo Clinic. Mayo Clin Proc. 2020;95(11):2467-86. DOI: 10.1016/j.mayocp.2020.08.030. PMID: 33153635
Franchini M, Marano G, Cruciani M, Mengoli C, Pati I, Masiello F, et al. COVID-19-associated coagulopathy. Diagnosis (Berl). 2020;7(4):357-63. DOI: 10.1515/dx-2020-0078. PMID: 32683333.
Merrill JT, Erkan D, Winakur J, James JA. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 202016(10):581-9. DOI: 10.1038/s41584-020-0474-5.
Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020;505:190-1. DOI: 10.1016/j.cca.2020.03.004. PMID: 32145275
Heidari-Beni F, Vahedian-Azimi A, Shojaei S, Rahimi-Bashar F, Shahriary A, Johnston TP, Sahebkar A. The Level of Procalcitonin in Severe COVID-19 Patients: A Systematic Review and Meta-Analysis. Adv Exp Med Biol. 2021;1321:277-86. DOI: 10.1007/978-3-030-59261-5_25. PMID: 33656733.
Liu ZM, Li JP, Wang SP, Chen DY, Zeng W, Chen SC, et al. Association of procalcitonin levels with the progression and prognosis of hospitalized patients with COVID-19. Int J Med Sci. 2020; 9;17(16):2468-76. DOI: 10.7150/ijms.48396. PMID: 33029089.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.